CANF — Can Fite Biopharma Share News
0.000.00%
Last trade - 00:00- $4.92m
- $1.93m
- $0.41m
Brief: Can-Fite Announces New Management Structure
Brief: Can-Fite Reports 2022 Financial Results & Provides Clinical Update
Brief: Can-Fite To Treat Decompensated Liver Cirrhosis Patients With Namodenoson Under Compassionate Use Setting
Brief: Can Fite Biopharma Ltd Files Prospectus Relates To Resale
Can-Fite BioPharma up on positive data from preclinical cancer drug studies
Brief: Can-Fite Namodenoson Inhibits Pancreatic Cancer In Preclinical Studies—A Patent Has Been Filed
Brief: Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering And Private Placement
Can Fite rises as it submits market registration plan to EMA for psoriasis treatment
Brief: Can-Fite Submits Market Registration Plan To EMA For Psoriasis Drug
Brief: Can-Fite Announces ADS Ratio Change
Brief: Can-Fite Reports Survival Benefits Of Namodenoson For Patients With Advanced Liver Cancer
Brief: Can-Fite’S Partner Vetbiolix Advances To European Multicentric Clinical Trial With Piclidenoson For The Treatment Of Pets’ Osteoarthritis
Brief: Can-Fite Positive New Data From It's Phase III Psoriasis Study Will Be Presented At An Industry Expert Summit
Brief: Can-Fite Says New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy
Brief: Can-Fite Reports Q2 2022 Financial Results & Provides Clinical Update
Can-Fite up on compassionate use nod for cancer drug in Romania
Brief: Can-Fite’s Says Drug Approved For Compassionate Use Treatment Of Advanced Liver Cancer Patients In Romania
Brief: Can-Fite To Present Positive Psoriasis Phase III Data At 31st European Academy Of Dermatology And Venerology Congress
Brief: Can-Fite Reports Progress In The Development Of Piclidenoson For Osteoarthritis In Pets Through Its Partner Vetbiolix